生命科学资讯

Other news to note for Dec. 19, 2025

Regulatory actions for Dec. 19, 2025

Appointments and advancements for Dec. 19, 2025

Financings for Dec. 19, 2025

Money raised by biopharma

Biopharma money raised: Jan. 1-Dec. 18, 2025

BioMarin to buy rare disease drugmaker Amicus for $4.8B

BioMarin to pay $4.8B for Amicus and its rare disease drugs

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Altimmune eyes phase 3 MASH trial as weight loss deepens

Chutes & Ladders—Pfizer RNA leader runs to Replicate

Cybin alters state to become Helus Pharma for Nasdaq trip

Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners

Senators point fingers over who blocked the rare disease voucher reauthorization

Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail

Biomarin buying rare disease company Amicus for $4.8B

Why Waters Corporation stock remains on buy lists - Risk Management & Risk Controlled Stock Alerts - Bölüm Sonu Canavarı

Galapagos TYK2 drug hits goal in one trial, misses in another

Biotech company Illumina loses venture building head Casas - - Global Venturing

Maintaining sexual identity in adult flies is an ongoing commitment